Do corticosteroids influence the disease course or mortality in Guillain-Barre' syndrome?
Article
in English
| IMSEAR
| ID: sea-84949
ABSTRACT
Forty-six patients of Guillain-Barre' Syndrome were randomized to receive either prednisolone (40 mg daily for 2 weeks and then tapered off) or placebo. The patients were followed up for 6 months and were assessed on an objective scale of disability. The improvement in mean disability grade was significantly better at 2 weeks and 4 weeks in the placebo group as compared to those who received corticosteroids. The difference persisted at 24 weeks, but was statistically insignificant. A greater proportion of patients in the placebo group had improved by at least 1 disability grade at all points of time. The group of patients treated with steroids took twice as long to improve by 1 disability grade as compared to those in the placebo group. At 6 months, 41.7% of the patients in the steroid group had recovered almost completely (good outcome) as compared to 54.5% of the patients is the placebo group. Corticosteroids, therefore, do not appear to benefit GBS patients, and may in fact, delay the recovery from acute illness.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Placebos
/
Polyradiculoneuropathy
/
Female
/
Humans
/
Male
/
Prednisolone
/
Prospective Studies
/
Follow-Up Studies
/
Treatment Outcome
/
Adult
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
/
Risk factors
Country/Region as subject:
Asia
Language:
English
Year:
1996
Type:
Article
Similar
MEDLINE
...
LILACS
LIS